Summary

The global radiotherapy market is projected to reach USD 9.62 billion by 2030 from USD 7.21 billion in 2024, growing at a CAGR of 4.9% during the forecast period. The technological advancements of radiotherapy technologies and systems is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of radiotherapy products affects the growth of the radiotherapy market.

“The external beam radiotherapy segment to hold the largest share of the market in 2024.”
Based on technology, radiotherapy is segmented into external beam radiotherapy, internal beam radiotherapy/ brachytherapy. The external beam radiotherapy segment is expected to dominate the radiotherapy market during the forecast period. The external beam radiotherapy segment is further divided into LINACs, Particle therapy and Conventional cobalt-60 teletherapy. With the growing prevalence of cancer, system and software enhancements, and the increasing adoption of external beam radiotherapy devices worldwide leads to the growth of this market segment.

“The external beam radiotherapy procedures segment to hold the largest share of the market in 2024.”
Based on procedure, the Radiotherapy market is segmented into external beam radiotherapy (EBRT) procedures and internal beam radiotherapy (IBRT)/brachytherapy procedures. The radiotherapy market is expected to be dominated by external beam radiotherapy procedures segment during the forecast period. The external beam radiotherapy procedures are expected to grow due to increased precision & accuracy of tumor targeting in this therapy..

“The hospitals companies segment to hold the largest share of the market in 2024.”
The end user market is segmented into hospitals and independent radiotherapy centres. Hospitals accounted for the largest share of the global radiotherapy market in 2023 during the forecasted years. This can be attributed to the major applications and large demand of radiotherapy accounted by hospital sector and the growing number of hospitals in emerging countries.

“The market in the APAC region is expected to register highest growth rate for Radiotherapy in 2024.”
The radiotherapy market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for radiotherapy was held by the market in the North American region, comprising the US and Canada. On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. The increasing market penetration opportunities in emerging APAC countries led to the growth of the radiotherapy market in this region.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1– 48%, Tier 2– 36%, and Tier 3– 16%
• By Designation: Directors– 14%, C-level– 10%, and Others– 76%
• By Region: North America– 40%, Europe– 32%, Asia Pacific– 20%, Latin America- 5%, MEA- 3%

The prominent players in the Radiotherapy market are Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Sumitomo Heavy Industries Ltd. (Japan), Carl Zeiss Meditec AG (Germany), Koninklijke Philips N.V. (Netherlands), among others.

Research Coverage
This report studies the radiotherapy market based on system, software & service, technology, application, procedure, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:
• Analysis of key drivers (Advancements in radiotherapy treatment technology, Growing patient population, Increasing initiatives to promote radiotherapy awareness, Growing use of particle therapy for cancer treatment), restraints (High cost of advanced lab consumables, Environmental sustainability concerns), opportunities (Lack of adequate healthcare infrastructure, High capital cost of radiotherapy, Complexity of radiotherapy), and challenges (Dearth of skilled personnel, Difficulties in visualizing tumors during radiotherapy, Risk of Radiation Exposure) influencing the growth of the radiotherapy market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the radiotherapy market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the radiotherapy market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the radiotherapy market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 MARKET STAKEHOLDERS 32
1.5 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 35
2.1.1.1 List of secondary sources 36
2.1.2 PRIMARY DATA 37
2.1.2.1 Key data from primary sources 37
2.2 MARKET ESTIMATION METHODOLOGY 39
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 40
2.2.2 USAGE-BASED MARKET ESTIMATION 42
2.2.3 PRIMARY RESEARCH VALIDATION 43
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 44
2.4 RESEARCH ASSUMPTIONS 45
2.4.1 STUDY ASSUMPTIONS 45
2.5 RESEARCH LIMITATIONS 45
2.6 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 RADIOTHERAPY MARKET OVERVIEW 51
4.2 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 52
4.3 EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,
BY TYPE AND REGION (2022) 52
4.4 RADIOTHERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.5 RADIOTHERAPY MARKET: REGIONAL MIX, 2022–2030 (USD MILLION) 54
 
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Advancements in radiotherapy treatment 56
5.2.1.2 Growing patient population 57
5.2.1.3 Increasing initiatives to promote radiotherapy awareness 57
5.2.1.4 Growing use of particle therapy for cancer treatment 58
5.2.2 RESTRAINTS 58
5.2.2.1 Lack of adequate healthcare infrastructure 58
5.2.2.2 High capital cost of radiotherapy 59
5.2.2.3 Complexity of radiotherapy 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Emerging economies 60
5.2.3.2 Favorable changes in US radiotherapy payment model 60
5.2.3.3 Government and private investments to meet rising demand for cancer treatment 61
5.2.4 CHALLENGES 61
5.2.4.1 Dearth of skilled personnel 61
5.2.4.2 Difficulties in visualizing tumors during radiotherapy 62
5.2.4.3 Risk of radiation exposure 62
5.3 REGULATORY ANALYSIS 63
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 63
5.3.2 REGULATORY LANDSCAPE 65
5.3.2.1 North America 65
5.3.2.1.1 US 65
5.3.2.1.2 Canada 66
5.3.2.2 Europe 67
5.3.2.3 Asia Pacific 68
5.3.2.3.1 China 68
5.3.2.3.2 Japan 68
5.3.2.3.3 India 69
5.4 REIMBURSEMENT SCENARIO 70
5.5 VALUE CHAIN ANALYSIS 71
5.5.1 RESEARCH & DEVELOPMENT 72
5.5.2 PROCUREMENT & PRODUCT DEVELOPMENT 72
5.5.3 MARKETING, SALES, AND DISTRIBUTION 72
5.6 SUPPLY CHAIN ANALYSIS 73
5.6.1 PROMINENT COMPANIES 73
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 73
5.6.3 END USERS 73
5.7 ECOSYSTEM ANALYSIS 74
5.8 PORTER’S FIVE FORCES ANALYSIS 75
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 76
5.8.2 BARGAINING POWER OF SUPPLIERS 76
5.8.3 BARGAINING POWER OF BUYERS 76
5.8.4 THREAT OF SUBSTITUTES 76
5.8.5 THREAT OF NEW ENTRANTS 76
5.9 KEY STAKEHOLDERS & BUYING CRITERIA 77
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 77
5.9.2 KEY BUYING CRITERIA 78
5.10 TRADE ANALYSIS 79
5.10.1 IMPORT DATA 79
5.10.2 EXPORT DATA 80
5.11 PATENT ANALYSIS 81
5.12 PRICING ANALYSIS 83
5.12.1 AVERAGE SELLING PRICE, BY PRODUCT 83
5.12.2 AVERAGE SELLING PRICE, BY COUNTRY 84
5.13 TECHNOLOGY ANALYSIS 86
5.13.1 KEY TECHNOLOGIES 86
5.13.1.1 Linear accelerators (LINACs) 86
5.13.1.2 Image-guided radiotherapy (IGRT) 86
5.13.1.3 Intensity-modulated radiotherapy (IMRT) 86
5.13.1.4 Particle therapy 86
5.13.1.5 Surface-guided radiotherapy (SGRT) 87
5.13.2 COMPLEMENTARY TECHNOLOGIES 87
5.13.2.1 Chemotherapy 87
5.13.2.2 Immunotherapy 87
5.13.2.3 Hyperthermia therapy 87
5.13.3 ADJACENT TECHNOLOGIES 88
5.13.3.1 Medical imaging technologies 88
5.13.3.2 Radioisotope production technologies 88
5.13.3.3 Systematic radiotherapy 88
5.13.3.4 Theranostics 89
5.14 CASE STUDY ANALYSIS 89
5.15 KEY CONFERENCES & EVENTS, 2024–2025 89
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91
5.17 INVESTMENT & FUNDING SCENARIO 91
5.18 UNMET NEEDS 93
5.19 IMPACT OF GENERATIVE AI ON RADIOTHERAPY MARKET 94
 
6 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 95
6.1 INTRODUCTION 96
6.2 SYSTEMS 96
6.2.1 CONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET 96
6.3 SOFTWARE & SERVICES 97
6.3.1 INCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH 97
7 RADIOTHERAPY MARKET, BY TECHNOLOGY 99
7.1 INTRODUCTION 100
7.2 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES 100
7.2.1 LINACS 101
7.2.1.1 Conventional LINACs 102
7.2.1.1.1 Long treatment duration to limit adoption 102
7.2.1.2 Stereotactic advanced electron/cobalt-60 LINACs 103
7.2.1.2.1 CyberKnife 104
7.2.1.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market 104
7.2.1.2.2 Gamma Knife 105
7.2.1.2.2.1 Ongoing product development and launches to support growth 105
7.2.1.2.3 TomoTherapy 106
7.2.1.2.3.1 High installation and maintenance costs to limit adoption 106
7.2.1.3 MRI LINACs 107
7.2.1.3.1 Real-time imaging advantage to propel growth 107
7.2.2 PARTICLE THERAPY 108
7.2.2.1 Cyclotrons 109
7.2.2.1.1 Enhanced outcomes and other advantages to boost adoption 109
7.2.2.2 Synchrotrons 110
7.2.2.2.1 Increasing investments in synchrotron facilities to drive market 110
7.2.2.3 Synchrocyclotrons 110
7.2.2.3.1 High space requirements to limit widespread adoption 110
7.2.3 CONVENTIONAL COBALT-60 TELETHERAPY 111
7.2.3.1 Complex dose delivery planning and radiation exposure to limit market adoption 111
7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 112
7.3.1 SEEDS 113
7.3.1.1 Adverse side-effects associated with seeds to limit adoption 113
7.3.2 AFTERLOADERS 114
7.3.2.1 Proper positioning and better control of isotopes in modern afterloaders to drive demand 114
7.3.3 IORT SYSTEMS 115
7.3.3.1 Rising adoption of electronic brachytherapy procedures to support growth 115
7.3.4 APPLICATORS 116
7.3.4.1 High risk of radiation exposure in manual applicators to limit growth 116
8 RADIOTHERAPY MARKET, BY APPLICATION 118
8.1 INTRODUCTION 119
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 119
8.2.1 PROSTATE CANCER 120
8.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth 120
8.2.2 BREAST CANCER 121
8.2.2.1 Therapeutic benefits of EBRT to drive market 121
8.2.3 LUNG CANCER 122
8.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market 122
8.2.4 HEAD & NECK CANCER 123
8.2.4.1 Noninvasive treatment of head & neck cancers to drive market 123
8.2.5 COLORECTAL CANCER 124
8.2.5.1 High incidence of colorectal cancer to support market growth 124
8.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 125
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 126
8.3.1 PROSTATE CANCER 128
8.3.1.1 Precision of brachytherapy to drive market 128
8.3.2 GYNECOLOGICAL CANCER 129
8.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 129
8.3.3 BREAST CANCER 129
8.3.3.1 Wide usage as replacement for traditional EBRT to drive market 129
8.3.4 CERVICAL CANCER 130
8.3.4.1 Effectiveness of combined brachytherapy-chemotherapy procedures to support adoption 130
8.3.5 PENILE CANCER 131
8.3.5.1 Rising awareness and effectiveness of brachytherapy to drive market 131
8.3.6 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 132
9 RADIOTHERAPY MARKET, BY PROCEDURE 134
9.1 INTRODUCTION 135
9.2 EXTERNAL BEAM RADIOTHERAPY 135
9.2.1 IMAGE-GUIDED RADIOTHERAPY 136
9.2.1.1 Growing demand in treating deep-seated tumors to drive market 136
9.2.2 INTENSITY-MODULATED RADIOTHERAPY 137
9.2.2.1 Advantages over 2D and 3D-CRT to boost adoption 137
 
9.2.3 3D CONFORMAL RADIOTHERAPY 138
9.2.3.1 High precision and minimal damage to nearby tissues to boost adoption 138
9.2.4 STEREOTACTIC RADIOTHERAPY 139
9.2.4.1 Minimally invasive procedure to drive end-user preference 139
9.2.5 PARTICLE THERAPY 140
9.2.5.1 High usage as primary mode of cancer treatment to sustain market growth 140
9.2.6 OTHER EXTERNAL BEAM RADIOTHERAPY PROCEDURES 141
9.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 142
9.3.1 LDR BRACHYTHERAPY 143
9.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption 143
9.3.2 HDR BRACHYTHERAPY 144
9.3.2.1 Possibility of tissue injury to affect adoption 144
9.3.3 PDR BRACHYTHERAPY 145
9.3.3.1 Combination of advantages to boost growth 145
10 RADIOTHERAPY MARKET, BY END USER 146
10.1 INTRODUCTION 147
10.2 HOSPITALS 147
10.2.1 HOSPITALS TO DOMINATE END-USER MARKET 147
10.3 INDEPENDENT RADIOTHERAPY CENTERS 148
10.3.1 LOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH 148
11 RADIOTHERAPY MARKET, BY REGION 150
11.1 INTRODUCTION 151
11.2 NORTH AMERICA 153
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 158
11.2.2 US 159
11.2.2.1 Changes in reimbursement scenario to drive growth 159
11.2.3 CANADA 161
11.2.3.1 Favorable initiatives from government and private organizations to boost market 161
11.3 EUROPE 163
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 168
11.3.2 GERMANY 169
11.3.2.1 Availability of novel radiotherapy products to drive market 169
11.3.3 FRANCE 171
11.3.3.1 Presence of advanced healthcare system to augment growth 171
11.3.4 UK 173
11.3.4.1 High incidence of cancer to drive market 173
 
11.3.5 SPAIN 175
11.3.5.1 Growing research activities on cancer care to promote growth 175
11.3.6 ITALY 177
11.3.6.1 Rising clinical trials and research activities in hospitals and universities to support growth 177
11.3.7 REST OF EUROPE 179
11.4 ASIA PACIFIC 180
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 187
11.4.2 JAPAN 187
11.4.2.1 Rising geriatric population to encourage growth 187
11.4.3 CHINA 189
11.4.3.1 Growing partnerships among market players to support growth 189
11.4.4 INDIA 191
11.4.4.1 Increasing preference for minimally invasive treatment to propel market 191
11.4.5 SOUTH KOREA 193
11.4.5.1 Increasing incidence of cancer to support market 193
11.4.6 AUSTRALIA 195
11.4.6.1 Growing cancer cases to fuel market 195
11.4.7 REST OF ASIA PACIFIC 197
11.5 LATIN AMERICA 199
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 204
11.5.2 BRAZIL 204
11.5.2.1 Increasing prevalence of cancer to fuel market 204
11.5.3 MEXICO 206
11.5.3.1 Rising target population to boost market growth 206
11.5.4 REST OF LATIN AMERICA 208
11.6 MIDDLE EAST & AFRICA 210
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 215
11.6.2 GCC COUNTRIES 215
11.6.2.1 Booming medical tourism to expedite growth 215
11.6.3 REST OF MIDDLE EAST & AFRICA 217
12 COMPETITIVE LANDSCAPE 219
12.1 INTRODUCTION 219
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 219
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET 219
12.3 REVENUE ANALYSIS, 2019–2023 221
12.4 MARKET SHARE ANALYSIS, 2023 221
12.4.1 EXTERNAL BEAM RADIOTHERAPY MARKET RANKING 223
12.4.2 INTERNAL BEAM RADIOTHERAPY MARKET RANKING 224
 
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 224
12.5.1 STARS 224
12.5.2 EMERGING LEADERS 224
12.5.3 PERVASIVE PLAYERS 225
12.5.4 PARTICIPANTS 225
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 226
12.5.5.1 Company footprint 226
12.5.5.2 Technology footprint 227
12.5.5.3 Application footprint 228
12.5.5.4 End-user footprint 229
12.5.5.5 Region footprint 229
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 230
12.6.1 PROGRESSIVE COMPANIES 230
12.6.2 RESPONSIVE COMPANIES 230
12.6.3 DYNAMIC COMPANIES 230
12.6.4 STARTING BLOCKS 231
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 232
12.7 COMPANY VALUATION & FINANCIAL METRICS 234
12.8 BRAND/PRODUCT COMPARISON 235
12.9 COMPETITIVE SCENARIO 236
12.9.1 PRODUCT LAUNCHES AND APPROVALS 236
12.9.2 DEALS 237
12.9.3 EXPANSIONS 238
13 COMPANY PROFILES 239
13.1 KEY PLAYERS 239
13.1.1 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.) 239
13.1.1.1 Business overview 239
13.1.1.2 Products/Services/Solutions offered 240
13.1.1.3 Recent developments 242
13.1.1.3.1 Product approvals 242
13.1.1.3.2 Deals 242
13.1.1.4 MnM view 244
13.1.1.4.1 Key strengths 244
13.1.1.4.2 Strategic choices 244
13.1.1.4.3 Weaknesses & competitive threats 244
13.1.2 ELEKTA 245
13.1.2.1 Business overview 245
13.1.2.2 Products/Services/Solutions offered 246
13.1.2.3 Recent developments 247
13.1.2.3.1 Product launches and approvals 247
13.1.2.3.2 Deals 248
13.1.2.3.3 Expansions 250
13.1.2.4 MnM view 250
13.1.2.4.1 Key strengths 250
13.1.2.4.2 Strategic choices 250
13.1.2.4.3 Weaknesses & competitive threats 250
13.1.3 ACCURAY INCORPORATED 251
13.1.3.1 Business overview 251
13.1.3.2 Products/Services/Solutions offered 252
13.1.3.3 Recent developments 253
13.1.3.3.1 Product approvals 253
13.1.3.3.2 Deals 254
13.1.3.3.3 Expansions 255
13.1.3.4 MnM view 255
13.1.3.4.1 Key strengths 255
13.1.3.4.2 Strategic choices 255
13.1.3.4.3 Weaknesses & competitive threats 255
13.1.4 IBA WORLDWIDE 256
13.1.4.1 Business overview 256
13.1.4.2 Products/Services/Solutions offered 257
13.1.4.3 Recent developments 258
13.1.4.3.1 Products launches 258
13.1.4.3.2 Deals 259
13.1.4.4 MnM view 260
13.1.4.4.1 Key strengths 260
13.1.4.4.2 Strategic choices 260
13.1.4.4.3 Weaknesses & competitive threats 260
13.1.5 VIEWRAY, INC. 261
13.1.5.1 Business overview 261
13.1.5.2 Products/Services/Solutions offered 262
13.1.5.3 Recent developments 263
13.1.5.3.1 Product approvals 263
13.1.5.3.2 Deals 263
13.1.6 BRAINLAB AG 265
13.1.6.1 Business overview 265
13.1.6.2 Products/Services/Solutions offered 265
13.1.7 PERSPECTIVE THERAPEUTICS 266
13.1.7.1 Business overview 266
13.1.7.2 Products/Services/Solutions offered 267
13.1.7.3 Recent developments 268
13.1.7.3.1 Deals 268
 
13.1.8 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION) 269
13.1.8.1 Business overview 269
13.1.8.2 Products/Services/Solutions offered 270
13.1.8.3 Recent developments 271
13.1.8.3.1 Deals 271
13.1.9 SUMITOMO HEAVY INDUSTRIES, LTD. 272
13.1.9.1 Business overview 272
13.1.9.2 Products/Services/Solutions offered 273
13.1.9.3 Recent developments 274
13.1.9.3.1 Product launches 274
13.1.9.3.2 Other developments 274
13.1.10 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG) 275
13.1.10.1 Business overview 275
13.1.10.2 Products/Services/Solutions offered 277
13.1.10.3 Recent developments 277
13.1.10.3.1 Products launches 277
13.1.11 MIM SOFTWARE INC. 278
13.1.11.1 Business overview 278
13.1.11.2 Products/Services/Solutions offered 278
13.1.11.3 Recent developments 279
13.1.11.3.1 Product launches and approvals 279
13.1.11.3.2 Deals 279
13.1.12 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 280
13.1.12.1 Business overview 280
13.1.12.2 Products/Services/Solutions offered 280
13.1.12.3 Recent developments 281
13.1.12.3.1 Product launches and approvals 281
13.1.13 PROVISION HEALTHCARE 282
13.1.13.1 Business overview 282
13.1.13.2 Products/Services/Solutions offered 282
13.1.14 MEVION MEDICAL SYSTEMS 283
13.1.14.1 Business overview 283
13.1.14.2 Products/Services/Solutions offered 283
13.1.14.3 Recent developments 284
13.1.14.3.1 Product launches 284
13.1.14.3.2 Deals 284
13.1.15 RAYSEARCH LABORATORIES 286
13.1.15.1 Business overview 286
13.1.15.2 Products/Services/Solutions offered 287
13.1.15.3 Recent developments 288
13.1.15.3.1 Product launches 288
13.1.15.3.2 Deals 288
13.1.16 KONINKLIJKE PHILIPS N.V. 290
13.1.16.1 Business overview 290
13.1.16.2 Products/Services/Solutions offered 291
13.1.16.3 Recent developments 292
13.1.16.3.1 Product launches 292
13.1.16.3.2 Deals 292
13.2 OTHER PLAYERS 293
13.2.1 INTRAOP MEDICAL, INC. 293
13.2.2 OPTIVUS PROTON THERAPY, INC. 294
13.2.3 BEBIG MEDICAL 295
13.2.4 P-CURE 296
13.2.5 THERAGENICS CORPORATION 297
13.2.6 PROTOM INTERNATIONAL 298
13.2.7 DOS ISOFT SA 299
13.2.8 ISOAID, LLC 300
13.2.9 MAGNETTX ONCOLOGY SOLUTIONS LTD. 301
14 APPENDIX 302
14.1 DISCUSSION GUIDE 302
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 309
14.3 CUSTOMIZATION OPTIONS 311
14.4 RELATED REPORTS 311
14.5 AUTHOR DETAILS 312